Asthma is one of the most common chronic diseases of childhood. While most children achieve asthma control, some develop severe and persistent disease that cannot be controlled with standard treatment options. Evolution in our understanding of asthma biology has led to the development of novel targeted therapies that target the underlying mechanisms of disease, several of which are now available for pediatric patients. This interactive activity combines artistic design, infographic presentation, and scientific expertise to deliver the latest advances in treatment of pediatric asthma, including current treatment guidelines, identifying poorly-controlled disease, and incorporating novel biologic therapy into the management of pediatric patients with asthma.
Pediatric Asthma: Evidence-Based Approaches in Poorly-Controlled Disease
Be part of the knowledge.™We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Pediatric Asthma: Evidence-Based Approaches in Poorly-Controlled Disease
Overview
Faculty
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family NJH Asthma Institute
Director, Asthma Program, National Jewish Health
Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health and University of Colorado School of Medicine
Aurora, COTarget Audience
This activity is designed for allergy/immunology and pulmonology providers including physicians, nurse practitioners, and physician assistants who manage pediatric patients with asthma.
Learning Objectives
- Incorporate current recommended treatment algorithms into the care of pediatric patients with asthma
- Identify children with poorly-controlled asthma for whom treatment escalation may be appropriate
- Integrate newer and more effective treatments for children with resistant or moderate-to-severe asthma based on safety and efficacy data and different asthma endotypes
Accreditation and Credit Designation Statements
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.Provider(s)/Educational Partner(s)
_small.png)
This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc.
Commercial Support
This activity is supported by independent educational grants from Genentech and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure Declarations
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Michael Wechsler, MD, MMSc has disclosed the following relevant financial relationships: AstraZeneca, Genentech, GlaxoSmithKline, Mylan, Novartis, Regeneron, Sanofi, Teva (Consultant); AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Teva (Contracted Research).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
- Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
- Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
- Sharon Powell, has no affiliations with commercial interests to disclose.
AKH, Inc.
- Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
- Patricia Brignoni, AKH Sr. Project Manager, has no affiliations with commercial interests to disclose.
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.How to Receive Your Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test and evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 65% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Media
Online, Web
Publication Dates
Release Date: 01/30/2020
End Date: This activity is no longer available for continuing education credit.
Recommended
Overview
Asthma is one of the most common chronic diseases of childhood. While most children achieve asthma control, some develop severe and persistent disease that cannot be controlled with standard treatment options. Evolution in our understanding of asthma biology has led to the development of novel targeted therapies that target the underlying mechanisms of disease, several of which are now available for pediatric patients. This interactive activity combines artistic design, infographic presentation, and scientific expertise to deliver the latest advances in treatment of pediatric asthma, including current treatment guidelines, identifying poorly-controlled disease, and incorporating novel biologic therapy into the management of pediatric patients with asthma.
Faculty
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family NJH Asthma Institute
Director, Asthma Program, National Jewish Health
Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health and University of Colorado School of Medicine
Aurora, COTarget Audience
This activity is designed for allergy/immunology and pulmonology providers including physicians, nurse practitioners, and physician assistants who manage pediatric patients with asthma.
Learning Objectives
- Incorporate current recommended treatment algorithms into the care of pediatric patients with asthma
- Identify children with poorly-controlled asthma for whom treatment escalation may be appropriate
- Integrate newer and more effective treatments for children with resistant or moderate-to-severe asthma based on safety and efficacy data and different asthma endotypes
Accreditation and Credit Designation Statements
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.Provider(s)/Educational Partner(s)
This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc.
Commercial Support
This activity is supported by independent educational grants from Genentech and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure Declarations
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Michael Wechsler, MD, MMSc has disclosed the following relevant financial relationships: AstraZeneca, Genentech, GlaxoSmithKline, Mylan, Novartis, Regeneron, Sanofi, Teva (Consultant); AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Teva (Contracted Research).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
- Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
- Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
- Sharon Powell, has no affiliations with commercial interests to disclose.
AKH, Inc.
- Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
- Patricia Brignoni, AKH Sr. Project Manager, has no affiliations with commercial interests to disclose.
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.How to Receive Your Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test and evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 65% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Media
Online, Web
Publication Dates
Release Date: 01/30/2020
End Date: This activity is no longer available for continuing education credit.
Facebook Comments